Tag: Staph Aureus

One PET, Two PET – Endocarditis and Positron Emission Tomography

PETs. We all love them. I have two of those, if the pictures in my “about me” page are any indication as well as the main pic of this post. This post will not cover our beloved (and sometimes only) friends. No, we will be talking about positron emission tomography, an imaging modality we usually

Continue reading

What the MRSA PCR? The Role of Nose PCR Swabs in Stewardship.

I recently wrote about the fact that all pneumonia are aspiration events. Depending on the colonization of the oropharynx and the volume of aspirate material plays a role in the development of subsequent disease. It stands to reason that, if we are able to figure out what is colonizing the oropharynx, we may be able

Continue reading

Creep? The Implications of Rising MICs for Vancomycin in Staphylococcus Aureus

Look, I know I have talked a lot about staphylococcus but there is a ton of details that go into the therapeutic aspects of it.  When it comes to staphylococcus aureus bacteremia, specifically MRSA, vancomycin is the first line therapy per the IDSA guidelines (1). I have discussed the issues with vancomycin dosing, and how

Continue reading

Echo? Who, what, when, how? Role of echo modality in Staph aureus bacteremia.

I absolutely love this song. I tried to learn how to play it on guitar, but I think you may need 7 strings for it, at least when I checked back in the day. This week we are adding to last week’s topic and talking about when and what type of echo to get. There

Continue reading

Adjunctive Rifampin in Staphylococcal Infections – Primer for Bacteremia and Endocarditis

The use of rifampin for staphylococcal infections is a bit controversial. The recommendation seems to be its use on infections involving prosthetic material, such as prosthetic valve endocarditis or prosthetic joint infections. For instance, the AHA infective endocarditis (1) guidelines recommends the addition of rifampin to a regimen consisting of vancomycin to infectious caused by

Continue reading

The Lyon Heart – The Virulent Coagulase-Negative Staphylococcus

Coagulase negative staphylococcus are generally skin commensals we tend to ignore when they pop up in one set of blood cultures as they tend to represent contamination of the blood culture bottles rather than true bacteremia. The most commonly seen is Staphylococcus epidermidis. The reason they are called “coagulase negative staphylococcus” is these organisms, compared

Continue reading

When To Get A TEE for Staphylococcus Aureus Bacteremia

Staphylococcus aureus bacteremia is a cause of severe morbidity and mortality, especially when it is complicated by infective endocarditis. The mortality of Staphylococcus aureus bacteremia is 20% (1) and that of infective endocarditis due to Staph aureus is much higher. Guidelines for the treatment of MRSA SAB (2) recommends the use of echocardiography, with TEE

Continue reading

Staphylococcus Aureus, the Inoculum Effect, Cefazolin, and Nafcillin: The Odyssey

Staphylococcus Aureus is a tough disease to treat, but luckily for MSSA we have pretty good antibiotics to treat this beast. The choice is usually between cefazolin, a first-generation cephalosporin, and Nafcillin, an anti-staphylococcal penicillin. My experience has been that cefazolin is usually the go to antibiotic for MSSA bacteremia, with nafcillin having a niche

Continue reading

MRSA Pneumonia Coverage – The Shorr Score

Empiric therapy for patients with pneumonia is not as clear cut as one would think. Guidelines tend to differ in terms of when to start empiric MRSA coverage, with some guidelines recommending initial therapy that covers MRSA in those who are admitted to the ICU (1), while other guidelines suggest to start MRSA therapy if

Continue reading

Dual Therapy for MRSA Bacteremia – We Still Haven’t Figured it out

So MRSA is really hard to kill. If you have done any sort of ID, you will not be surprised by that statement. MRSA bacteremia has a high relapse rate. Because of this, people have tried multiple types of antibiotics, including Daptomycin and Ceftaroline, have been used with minimal change in the outcomes. In the

Continue reading